A comprehensive view of European Medicines Agency (EMA). This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

European Medicines Agency validates Bristol Myers' application for Opdivo nivolumab plus Yervoy ipilimumab for the first-line treatment of adult patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer
Published: May 06, 2024 by Bristol-Myers Squibb Co.
Amgen submits marketing authorization application to the European Medicines Agency for teprotumumab treatment for moderate to severe thyroid eye disease in adults; if approved, teprotumumab would be the first approved medicine for TED in the EU
Published: April 29, 2024 by PharmaBiz (India)
CHMP adopts positive opinion recommending approval of Bristol Myers Squibb’s Opdivo nivolumab in combination with Cisplatin and Gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma
Published: April 26, 2024 by Bristol-Myers Squibb Co.
Phase 3 study of Roche's OCREVUS subcutaneous injection shows near-complete suppression of multiple sclerosis relapse activity and lesions; approval anticipated from FDA and EMA in 2024
Published: April 17, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Bristol-Myers Squibb receives EMA's positive opinion on anemia therapy, bolsters collaborative health initiatives, and continues technological advancement in disease treatment
Published: February 24, 2024 by Industry Intelligence Inc.

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count